Covariate | HR (95% CI) | Two-sidedPvalue |
---|---|---|
PIK3CA mutation a | ||
Treatment (Lap + Pac/Pbo + Pac) (n = 171) | 0.41 (0.27, 0.62) | <0.0001 |
HR status (negative/positive) | 0.86 (0.62, 1.20) | 0.379 |
Metastatic sites (visceral/nonvisceral only) | 0.77 (0.50, 1.17) | 0.218 |
PIK3CA mutation (yes/no) | 1.31 (0.84, 2.07) | 0.238 |
Treatmenta PIK3CA interaction | 1.76 (0.91, 3.43) | 0.095 |
PTEN low | ||
Treatment (Lap + Pac/Pbo + Pac) (n = 355) | 0.59 (0.42, 0.83) | 0.003 |
HR status (negative/positive) | 1.01 (0.81, 1.26) | 0.948 |
Metastatic sites (visceral/nonvisceral only) | 0.66 (0.48, 0.89) | 0.007 |
PTEN low (yes/no) | 1.10 (0.81, 1.52) | 0.537 |
Treatmenta PTEN low interaction | 0.75 (0.48, 1.18) | 0.219 |